Arven Pharmaceuticals

Arven started to develop inhalation products and biologics in 2007. Main goal of the company is to focus on specific product areas and -difficult to make- products. Taking into account the rapidly changing dynamics of global regulatory environment, Toksoz Group decided to start up Arven dedicated only to development and manufacture of inhalation products and biologics. To support this vision, Arven established teams of highly qualified and dedicated research scientists, as well as build a brand new 28,000 square meter manufacturing facility located in the Kirklareli, Turkey. Arven strives for developing products for global market, with strategy of One Product...

Biotechnology,biotechnology product development,inhalation,inhalation product development,g-csf,and filgrastim

Arven pharmaceuticals operates in the Pharmaceutical manufacturing industry.

Arven pharmaceuticals's revenue is 11m - 100m

Arven pharmaceuticals has 51 - 200 employees.